IMDX.US Insight Molecular Diagnostics Inc.

Healthcare Health Care Equipment & Supplies USA Stocks
2.14 USD
Close of Nov 15, 2026
2.07 7.51
Market cap
USD 70.0M
P/E
-
P/B
87.06x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IMDX.US undervalued?

Graham number

The Graham number of Insight Molecular Diagnostics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Insight Molecular Diagnostics Inc. fundamental analysis

No fundamental analysis for Insight Molecular Diagnostics Inc. yet.

Insight Molecular Diagnostics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immun…

Full company profile